CN110642937B - 多肽衍生物、纳米纤维及其应用 - Google Patents
多肽衍生物、纳米纤维及其应用 Download PDFInfo
- Publication number
- CN110642937B CN110642937B CN201910962002.1A CN201910962002A CN110642937B CN 110642937 B CN110642937 B CN 110642937B CN 201910962002 A CN201910962002 A CN 201910962002A CN 110642937 B CN110642937 B CN 110642937B
- Authority
- CN
- China
- Prior art keywords
- polypeptide derivative
- nap
- ffgsssr
- igf
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 108
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 106
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 105
- 239000002121 nanofiber Substances 0.000 title claims abstract description 38
- 238000010438 heat treatment Methods 0.000 claims abstract description 19
- 201000000585 muscular atrophy Diseases 0.000 claims abstract description 19
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 17
- 238000001816 cooling Methods 0.000 claims abstract description 16
- 206010028289 Muscle atrophy Diseases 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 64
- 238000002360 preparation method Methods 0.000 claims description 35
- 239000008055 phosphate buffer solution Substances 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract description 59
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 13
- 230000027455 binding Effects 0.000 abstract description 11
- 238000003860 storage Methods 0.000 abstract description 10
- 230000004071 biological effect Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- 238000005406 washing Methods 0.000 description 35
- 239000000017 hydrogel Substances 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000002609 medium Substances 0.000 description 26
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 17
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 239000007790 solid phase Substances 0.000 description 16
- 239000011521 glass Substances 0.000 description 15
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 14
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000020763 muscle atrophy Effects 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 210000003098 myoblast Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010186 staining Methods 0.000 description 10
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000012894 fetal calf serum Substances 0.000 description 9
- 210000000497 foam cell Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 8
- 229960003957 dexamethasone Drugs 0.000 description 8
- 238000010532 solid phase synthesis reaction Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 230000004155 insulin signaling pathway Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000006372 lipid accumulation Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- DVBUCBXGDWWXNY-SFHVURJKSA-N (2s)-5-(diaminomethylideneamino)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C3=CC=CC=C3C2=C1 DVBUCBXGDWWXNY-SFHVURJKSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 4
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000012295 chemical reaction liquid Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101150092476 ABCA1 gene Proteins 0.000 description 3
- 101150037123 APOE gene Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 description 3
- 108091007410 T-AKT Proteins 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- -1 small molecule compounds Chemical class 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N 2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- VIBOGIYPPWLDTI-UHFFFAOYSA-N 2-naphthylacetic acid Chemical compound C1=CC=CC2=CC(CC(=O)O)=CC=C21 VIBOGIYPPWLDTI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000662429 Fenerbahce Species 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 208000025494 Aortic disease Diseases 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002948 appetite stimulant Substances 0.000 description 1
- 229940029995 appetite stimulants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
Abstract
Description
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910962002.1A CN110642937B (zh) | 2019-10-11 | 2019-10-11 | 多肽衍生物、纳米纤维及其应用 |
PCT/CN2020/119949 WO2021068884A1 (zh) | 2019-10-11 | 2020-10-09 | 多肽衍生物、纳米纤维及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910962002.1A CN110642937B (zh) | 2019-10-11 | 2019-10-11 | 多肽衍生物、纳米纤维及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110642937A CN110642937A (zh) | 2020-01-03 |
CN110642937B true CN110642937B (zh) | 2021-04-06 |
Family
ID=68993782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910962002.1A Active CN110642937B (zh) | 2019-10-11 | 2019-10-11 | 多肽衍生物、纳米纤维及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110642937B (zh) |
WO (1) | WO2021068884A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
CN112358529B (zh) * | 2020-11-12 | 2022-08-05 | 南开大学 | 多肽及其衍生物和水凝胶、以及在制备预防和/或治疗i型糖尿病药物中的应用 |
CN113321706B (zh) * | 2021-07-15 | 2022-01-07 | 南开大学 | 一种自组装多肽衍生物及其制备的水凝胶 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987001038A1 (en) * | 1985-08-22 | 1987-02-26 | Commonwealth Scientific And Industrial Research Or | Peptide analogues of mammalian insulin-like growth factor-1 |
EP1989226A4 (en) * | 2006-03-06 | 2009-11-18 | Caregen Co Ltd | PEPTIDES HAVING INSULIN-TYPE GROWTH FACTOR ACTIVITY 1 AND USES THEREOF |
FR2943346B1 (fr) * | 2009-03-19 | 2011-05-06 | Univ Paris Curie | Peptides modulant l'activite de l'igf-1 et leurs applications |
NZ708091A (en) * | 2012-12-18 | 2018-03-23 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
JP2016535080A (ja) * | 2013-10-02 | 2016-11-10 | ノバルティス アーゲー | 療法における使用のためのインスリン様成長因子模倣物 |
CN105497891A (zh) * | 2015-12-23 | 2016-04-20 | 南开大学 | 一种多肽水凝胶作为蛋白疫苗佐剂的应用及蛋白疫苗 |
CN107522772B (zh) * | 2017-08-07 | 2020-05-19 | 南开大学 | 短肽、其作为疫苗佐剂的应用及以所述短肽作为疫苗佐剂的疫苗 |
CN107778367B (zh) * | 2017-11-14 | 2020-09-29 | 南开大学 | 多肽、其应用及包含所述多肽的药物 |
CN109957000B (zh) * | 2017-12-14 | 2022-08-02 | 南开大学 | 一种促进细胞增殖的多肽衍生物及其制备方法及应用 |
CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
-
2019
- 2019-10-11 CN CN201910962002.1A patent/CN110642937B/zh active Active
-
2020
- 2020-10-09 WO PCT/CN2020/119949 patent/WO2021068884A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN110642937A (zh) | 2020-01-03 |
WO2021068884A1 (zh) | 2021-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110642937B (zh) | 多肽衍生物、纳米纤维及其应用 | |
TWI532495B (zh) | 藥學製劑 | |
US20110117195A1 (en) | Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers | |
JP2017501136A (ja) | バイオファブリケーション及びプリンティングのための構成要素としての自己組織化ペプチド、ペプチド模倣体及びペプチド結合体 | |
CN107952078B (zh) | 一种载药体系的合成方法及其用途 | |
CN113774027A (zh) | 一种蜂巢状GelMA微球在构建肿瘤模型中的应用 | |
CN112353950A (zh) | 一种siRNA纳米递送***的制备方法及其在***癌中的应用 | |
CN112816697A (zh) | 抑制破骨细胞活性及治疗骨质疏松的试剂及其应用 | |
Zhang et al. | Injectable supramolecular hybrid hydrogel delivers IL-1β-stimulated exosomes to target neuroinflammation | |
US10258669B2 (en) | Polypeptide and polypeptide complex for suppressing tumor metastasis and treating leukemia as well as preparation method therefor and application thereof | |
Mahoney et al. | Adipose derived delivery vehicle for encapsulated adipogenic factors | |
Liu et al. | Peptide modified geniposidic acid targets bone and effectively promotes osteogenesis | |
CN114478706B (zh) | 用于三维培养纤维网状结构多肽及其应用 | |
Kronstadt et al. | Assessment of anti-inflammatory bioactivity of extracellular vesicles is susceptible to error via media component contamination | |
EP4137505A1 (en) | Self-assembling peptide | |
CN114426573B (zh) | 一种Nur77磷酸化衍生肽及其在制备促进胚胎植入的药物中的应用 | |
US10881683B2 (en) | Nucleic acid molecule | |
CN115919804A (zh) | 诱导Treg细胞分化的纳米载体***及其在RA治疗中的应用 | |
US10000534B2 (en) | Peptide having osteoblast proliferation activity and periodontal ligament fibroblast proliferation activity, and use of same | |
CN113004372A (zh) | 一种免疫多肽及其应用 | |
CN111632026A (zh) | 一种自组装短肽水凝胶及其用途 | |
CN115581766A (zh) | 一种结合PD-L1/TGFβ双功能抗体融合蛋白液体制剂 | |
Li et al. | The effect of bioactivity of airway epithelial cells using methacrylated gelatin scaffold loaded with exosomes derived from bone marrow mesenchymal stem cells | |
Liu et al. | Preparation of Neuropeptide Nanoparticle and Its Mechanism in Corneal Nerve Regeneration in Substance P-Neurokinin 1 Receptor Signaling Pathway | |
CN108324946B (zh) | miRNA708、和/或301簇的微小RNA在改善心脏功能方面的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231031 Address after: Unit 8C, Block A, Huakai Fugui 1 #, No. 36, Dongda Road, Wenquan Street, Gulou District, Fuzhou City, 350000, Fujian Province Patentee after: Corvette (Fuzhou) Medical Technology Co.,Ltd. Address before: 300071 Tianjin City, Nankai District Wei Jin Road No. 94 Patentee before: NANKAI University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240202 Address after: Unit 8B, Building A, Huakai Fugui, No. 36 Dongda Road, Wenquan Street, Gulou District, Fuzhou City, Fujian Province, 350000 Patentee after: Aikiev (Fujian) Biotechnology Research Co.,Ltd. Country or region after: China Address before: Unit 8C, Block A, Huakai Fugui 1 #, No. 36, Dongda Road, Wenquan Street, Gulou District, Fuzhou City, 350000, Fujian Province Patentee before: Corvette (Fuzhou) Medical Technology Co.,Ltd. Country or region before: China |